Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Vitafoods IndiaVitafoods India
Not Confirmed
Not Confirmed
05-07 February, 2025
33rd NZW-Hamburg33rd NZW-Hamburg
Not Confirmed
Not Confirmed
07-09 February, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Vitafoods IndiaVitafoods India
Industry Trade Show
Not Confirmed
05-07 February, 2025
33rd NZW-Hamburg33rd NZW-Hamburg
Industry Trade Show
Not Confirmed
07-09 February, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
04 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/corerx-societal-cdmo-and-bend-bioscience-unite-under-the-bend-bioscience-brand-to-provide-world-class-cdmo-offering-302237436.html
09 Apr 2024
// CONTRACTPHARMA
https://www.contractpharma.com/contents/view_breaking-news/2024-04-09/corerx-completes-acquisition-of-societal-cdmo/
28 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/28/2837478/30326/en/Societal-CDMO-Enters-Into-Definitive-Agreement-to-be-Acquired-by-CoreRx-Inc.html
01 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/01/2821861/30326/en/Societal-CDMO-and-Benuvia-Sign-Co-Marketing-Agreement-Designed-to-Promote-Complementary-CDMO-and-API-Manufacturing-Services-to-Drug-Developers.html
05 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/01/05/2804875/30326/en/Societal-CDMO-Reports-Inducement-Grants-for-New-Staff.html
08 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/08/2776715/30326/en/Societal-CDMO-Reports-Third-Quarter-2023-Financial-Results.html
Details:
Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Brand Name: Endoxifen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Atossa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 23, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...
Product Name : Endoxifen
Product Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2023
Details:
Under the agreement, Societal CDMO will provide to support the ongoing clinical development of iNexin™, a patented new chemical entity based on company's aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
Lead Product(s): iNexin
Therapeutic Area: Ophthalmology Brand Name: iNexin
Study Phase: Phase IProduct Type: Peptide
Recipient: Xequel Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 08, 2023
Lead Product(s) : iNexin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Xequel Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Societal CDMO will provide to support the ongoing clinical development of iNexin™, a patented new chemical entity based on company's aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
Product Name : iNexin
Product Type : Peptide
Upfront Cash : Undisclosed
May 08, 2023